SCHEMBL13623638

SCHEMBL13623638

CCC(=O)c1cncnc1NCCS

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 10/20 0.37
CYP1A2 P05177 7/20 0.37
HSD17B10 Q99714 6/20 0.37
ALOX15 P16050 3/20 0.37
TSHR P16473 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2D6 P10635 3/20 0.36
CYP2C19 P33261 5/20 0.36
ALDH1A1 P00352 4/20 0.36
LMNA P02545 2/20 0.36
KDR P35968 1/20 0.35
KDM4E B2RXH2 3/20 0.35
HPGD P15428 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
AGTR1 P30556 2/20 0.32
AGTR2 P50052 2/20 0.32
AURKA O14965 1/20 0.32
RPS6KB1 P23443 1/20 0.32
CHRNA7 P36544 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13610815 0.81 CYP3A4 (0.36) CYP3A4CYP1A2HSD17B10ALOX15TSHR
SCHEMBL13610835 0.71 HSD17B10 (0.47) CYP3A4CYP1A2HSD17B10ALOX15TSHR
SCHEMBL6859050 0.69 HSP90AB1 (0.34) HSD17B10TSHRKDM4ETDP1MEN1
SCHEMBL23094646 0.67 KMT2A (0.34) HSD17B10TSHRALDH1A1LMNAHPGD
SCHEMBL11584012 0.67 AGTR1 (0.47) CYP3A4CYP1A2HSD17B10ALOX15TSHR
SCHEMBL13624525 0.66 MAPK14 (0.42) CYP3A4CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL13623635 0.66 HCAR3 (0.57)
SCHEMBL19151158 0.63 PDE4A (0.47) CYP3A4CYP1A2HSD17B10TSHRALDH1A1
SCHEMBL8578869 0.63 ABL1 (0.34)
SCHEMBL30636642 0.63 NLRP3 (0.43) HSD17B10TSHRALDH1A1KDRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090280106-A1 Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use BAYER PHARMACEUTICALS CORPORATION (US) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090280106-A1 Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use ADCYAP1R1, VIPR2, ADCY2 CYP3A4 3091/4885CYP1A2 2466/4885HSD17B10 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.